A Phase I Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors and Lymphomas.
Phase of Trial: Phase I
Latest Information Update: 03 Nov 2011
At a glance
- Drugs NTB 011 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 03 Nov 2011 Planned End Date changed from 1 May 2015 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 03 Nov 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Mar 2011 Additional lead trial centre identified as reported by Barbara Ann Karmanos Cancer Institute.